Previous 10 | Next 10 |
Xenetic Biosciences (NASDAQ:XBIO): Q3 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.35M (+191.7% Y/Y) beats by $0.15M. Press Release For further details see: Xenetic Biosciences EPS misses by $0.01, beats on revenue
Company advancing XCART TM pre-clinical development plan toward IND-enabling studies Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placement Continued royalty stream growth through license agreement with PolyX...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re diving back into the stock market again today with a look at the biggest pre-market stock movers for Thursday! Source: Shutterstock We’ve got loads of stock news to discus...
Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCART FRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing ...
FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, tod...
Analysts Are Bullish On These Penny Stocks Finding penny stocks to buy doesn’t have to be overly complicated. Research is a big part of identifying trends and opportunities early. Sometimes analysts can be helpful in adding some insight to your DD process. In this article, we...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another week, another list of short squeeze stocks for investors to examine. Source: Shutterstock This massive trend continues to be top of mind for many investors. But in case you’ve missed out on these oppo...
Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies Strong royalty growth with PolyXen® platform technology Bolstered cash position with recently completed $12.5 million private placement FRAMINGHAM, MA / ACCESSWIRE...
Gainers: Powerbridge Technologies PBTS +54%. IEC Electronics IEC +47%. The ExOne XONE +44%. AeroCentury (NYSE:ACY) +31%. NanoVibronix (NASDAQ:NAOV) +24%. KnowBe4 KNBE +21%. Xenetic Biosciences (NASDAQ:XBIO) +21%. Sesen Bio (NASDAQ:SESN) +21%. Opendoor Technologies OPEN ...
Gainers: NanoVibronix (NASDAQ:NAOV) +27%, Apyx Medical (NASDAQ:APYX) +20%, Xenetic Biosciences (NASDAQ:XBIO) +19%, Doximity (NYSE:DOCS) +15%, OncoCyte (NASDAQ:OCX) +14%. Losers: MedAvail (NASDAQ:MDVL) -51%, LifeStance Health (NASDAQ:LFST) -49%...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...